CHRU Nancy - Hopitaux Brabois

The department is conducting a study on metastatic colorectal cancer, exploring second‑line chemotherapy combined with targeted agents to improve disease control and patient survival.

• Evaluation of FOLFOX/FOLFIRI plus bevacizumab or fruquintinib
• Assessment of disease control rate at four months
• Focus on treatment efficacy in advanced colorectal tumors

This research is carried out at CHRU Nancy - Hopitaux Brabois, aiming to offer new options for patients with advanced digestive system malignancies.

Trials are evaluating therapies for relapsed acute lymphoblastic leukemia in children, comparing novel immunotherapies and consolidation strategies to boost long‑term remission.

• Comparison of inotuzumab ozogamicin versus mitoxantrone induction
• MRD‑guided consolidation with blinatumomab
• Measurement of event‑free survival and four‑year disease‑free survival

At CHRU Nancy - Hopitaux Brabois, the goal is to refine treatment pathways for pediatric patients facing hematologic relapse.

A study focuses on Light Chain (AL) Amyloidosis, testing a new antibody therapy alongside standard care to reduce mortality and assess long‑term safety in advanced disease.

• Investigation of birtamimab added to standard of care
• Primary endpoint of time to all‑cause mortality in Mayo Stage IV patients
• Open‑label extension evaluating extended safety profile

Conducted at CHRU Nancy - Hopitaux Brabois, the trial seeks to bring innovative treatment options to patients with severe systemic amyloidosis.